Seeking Alpha

Surface Oncology Reports Financial Results and Business Highlights for Second Quarter 2022

– SRF388 clinical data presented at 2022 ASCO Annual Meeting demonstrated monotherapy responses in two different indications, combination activity and notable disease stabilization – – Interim SRF617 ...
Business Insider

Vaccinex, Inc. Announces Research Collaboration Employing ActivMAb® Platform Technology and Antibody License Option Agreement with Surface Oncology

ROCHESTER, N.Y., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a privately-held clinical-stage biotechnology company engaged in the development of therapeutic monoclonal antibodies to treat ...
Reuters

Surface Oncology Files For Common Stock Offering Of Up To $50 Million

Healthcare & Pharmaceuticalscategory Novo Nordisk's stellar Wegovy-fuelled run of hiking sales guidance could be ending 5:12 AM UTC · Updated ago Healthcare & Pharmaceuticalscategory Aid funding ...
Nasdaq

Surface Oncology to Present Preclinical Data for Lead Clinical Programs at the Society for Immunotherapy of Cancer 2021 Annual Meeting

CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor ...
Business Insider

Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Candidate SRF617

CAMBRIDGE, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor ...
Seeking Alpha

Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, ...
ksn.com

Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences

About Surface Oncology Surface is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned programs; ...
WREG

Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab ...

– Management to host conference call to discuss SRF388 data and other corporate updates today at 8:30 a.m. ET – CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a ...
The Business Journals

Surface Oncology CEO Rob Ross returns, with new $150M-backed startup

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The new immuno-oncology company ...
WGNO

Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor ...
Reuters

Novartis signs $170 million immuno-oncology pact with Surface

ZURICH (Reuters) - Novartis AG has struck a $170 million alliance with U.S.-based Surface Oncology as it seeks to boost its portfolio of medicines that help the body's immune system fight cancer. The ...